An important regulatory milestone has been pushed back to late December, although investors will be awaiting voting results from a meeting in mid-November.
News & Analysis: Amarin
With stock valuations down and out, the timing may be ripe for pharma and big biotech companies to start bargain hunting.
These revenue-producing, possible acquisition candidates may be the right medicine to heal your portfolio.
Amarin's Vascepa just might be a blockbuster.
These biotech stocks are great picks -- but for very different reasons.
The Rule of 40 is a quick and dirty way to value stocks before you add them to your portfolio.
Investors unloaded shares of this Irish biotech following a setback from the FDA.
Biotech stocks tend to react badly to advisory committee meetings.
These three health care stocks deserve your undivided attention right now.
Two mid-cap biotechs. Two tremendously successful drugs already on the market. But which is the better long-term stock pick?